BridgeMD
The headache- and migraine-inducing effects of apremilast in women with migraine without aura
EU CTIS ID: 2026-525987-16-00
What this study is testing
We will test the ability of a single oral administration of apremilast (30 mg) to induce migraine in women with a history of migraine without aura.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Healthy women with a diagnosis of episodic migraine without aura according to the International Classification
- Safe contraception (including hormonal therapies, intrauterine devices and/or oral pills) during the entire period of the study
- Age: 18-65 years
- Weight: 50-90 kg
- Fluency in Danish or English
You likely can't join if
- Any other type of headache (excluding < 3 days of tension-type headache per month), according to the International Classification
- Positive pregnancy test at the Screening and/or before the start of each experimental day (first and second experimental administration)
- Known allergy to any component of apremilast “Stada”
- Member of investigational site staff or relative of investigators
- Headache less than 24 hours before the start of the experiment
- Drinking coffee, cola or alcohol less than 8 hours before the start of the experiment
See the full eligibility criteria
- Healthy women with a diagnosis of episodic migraine without aura according to the International Classification
- Safe contraception (including hormonal therapies, intrauterine devices and/or oral pills) during the entire period of the study
- Age: 18-65 years
- Weight: 50-90 kg
- Fluency in Danish or English
- Any other type of headache (excluding < 3 days of tension-type headache per month), according to the International Classification
- Positive pregnancy test at the Screening and/or before the start of each experimental day (first and second experimental administration)
- Known allergy to any component of apremilast “Stada”
- Member of investigational site staff or relative of investigators
- Headache less than 24 hours before the start of the experiment
- Drinking coffee, cola or alcohol less than 8 hours before the start of the experiment
- Assumption of analgesic medications in the 24 hours preceding the experimental days
- History or clinical evidence of severe psychiatric disorders (including anxiety or depression) and hepatic and/or renal impairment
- Underweight patients (body mass index < 18.5 kg/m²)
- Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
- Anamnestic or clinical signs of diseases of any kind considered by the investigating physician relevant for participation in the study
- Use of concomitant medications that have changed in dosage within 14 days prior to screening or are expected to change during the study period
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.